PhotoCure ASA (OSL:PHO)
kr 49.3 0.4 (0.82%) Market Cap: 1.34 Bil Enterprise Value: 1.05 Bil PE Ratio: 94.81 PB Ratio: 2.67 GF Score: 78/100

Q2 2019 Photocure ASA Earnings Call Transcript

Aug 07, 2019 / 06:30AM GMT
Release Date Price: kr52 (+0.78%)
Daniel Schneider
Photocure ASA - President & CEO

All right. Well, good morning and welcome to Photocure's 2019 Second Quarter Update. I'm Dan Schneider, CEO and President of Photocure. With me today is Erik Dahl, CFO. I'll take you through a number of slides before Erik wraps up with financials, and then we'll go to Q&A, if that's okay.

A reminder, the usual disclaimers are in effect for today's presentation.

I thought I'll start today's presentation a little bit around the strategy, the 4 steps to become a transformative, multiproduct, bladder cancer company: step 1 is accelerate, growing the Cysview/Hexvix line. I think we put, and you know, considerable investment and effort and are starting to see the acceleration. This expansion and acceleration is important to setting up the foundation of the future for Photocure.

Expand. Our recent indication late last summer/early fall launched into the surveillance market open up a tremendous opportunity for Photocure as the market quadruples in terms of size for us to address. New geographies, whether it be Canada, New

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot